Preparation of Recombinant Human Insulin-Like Tender - 139449137

Procurement Summary

Country: Poland

Summary: Preparation of Recombinant Human Insulin-Like Growth Factor - 1 (Mecasermin) for Administration in Generally Available Syringes of Small Capacity and High Accuracy: - Vial/Ampoule with a Capacity Of...

Deadline: 27 Apr 2026

Posting Date: 13 Apr 2026

Other Information

Notice Type: Tender

TOT Ref.No.: 139449137

Document Ref. No.: 250843-2026

Competition: ICB

Financier: Self Financed

Purchaser Ownership: Public

Tender Value: Refer Document

CPV Classification

33642100 - Pituitary, hypothalamic hormones and analogues

Purchaser's Detail

Name: Login to see tender_details

Address: Login to see tender_details

Email: Login to see tender_detailsLogin to see details

Tender Details

Preparation of recombinant human insulin-like growth factor - 1 (mecasermin) for administration in generally available syringes of small capacity and high accuracy: - vial/ampoule with a capacity of... Recombinant human insulin-like preparation growth factor - 1 (mecasermin) for administration in generally available low-capacity and high-precision syringes: - vial/ampoule with a capacity of 50 mg the subject of the order is the supply of a recombinant human insulin-like factor growth - 1 (mecasermin) for administration in generally available syringes of low capacity and high precision: - vial/ampoule with a capacity of 1. the total size of the basic order is: 136, 810 mg. 2. the ordering party reserves the right to increase the quantity of the subject of the order, however, not more than 15% of the basic order, in an amount of 20, 250 mg. 3. the ordering party anticipates a change in the size of the subject of the order during the term of the contract, i.e. it is possible to reduce the ordered volume by 20%. the size of the basic order, in the event of objective and justified needs, in particular changes in patient demand - this change depends on the internal needs of direct recipients, which may arise during execution of the order and leaves it solely to your decision. when submitting an offer, the contractor acknowledges the possibility of various circumstances affecting changes in demand. 4. the offered medicine is registered and reimbursed to treatment of patients with short stature due to severe primary igf-1 deficiency with recombinant igf-1. 5. the offered preparation must meet the conditions...
Document Type: Contract Notice Reference Number: ZZP.ZP.411.57.2026 Contract Type: supplies Authority Type: cga Doc Title: Preparation of recombinant human insulin-like growth factor - 1 (mecasermin) for administration in generally available syringes with small capacity and high accuracy: - vial/ampoule with capacity Dispatch Date: 2026-04-10 Publish Date: 2026-04-13 Submission Date: 2026-04-27

Documents

 Tender Notice